CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD19 单核苷酸多态性对 FMC63-CAR-T 细胞治疗结局的临床影响
英文原题：Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy.
查看英文原题
Clinical Impact of Single Nucleotide Polymorphism in CD-19 on Treatment Outcome in FMC63-CAR-T Cell Therapy.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）-T细胞疗法对复发/难治性弥漫性大B细胞淋巴瘤（r/r DLBCL）患者有效，缓解率为63-84%，完全缓解率为43-54%。靶抗原CD19的常见胚系变异可能引发对CAR-T 细胞疗法的不同反应。CD19基因单核苷酸多态性rs2904880编码CD19抗原第174位氨基酸的亮氨酸或缬氨酸，在研究的DLBCL患者中普遍存在，占51%。在一项临床结果的回顾性比较分析中，CD19 L174与V174携带者之间存在显著差异：中位无进展生存期分别为22个月与6个月（p = 0.06），总生存期分别为37个月与8个月（p = 0.11），完全缓解率分别为51%与30%（p = 0.05），难治性疾病率分别为14%与32%（p = 0.04）。CD19的单核苷酸多态性被证明影响FMC63-anti-CD19-CAR-T 细胞疗法的治疗结果，CD19次要等位基因L174预示良好的治疗结果。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T cell therapy is effective in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL) with response rates of 63-84% and complete response observed in 43-54%. Common germline variants of the target antigen CD19 may elicit different responses to CAR-T cell therapy. The CD19 gene single nucleotide polymorphism rs2904880 encoding leucine or valine at amino acid position 174 of the CD19 antigen was prevalent in 51% of the studied DLBCL patients.
In a retrospective comparative analysis of clinical outcome, there were significant differences in CD19 L174 versus V174 carriers: the median time of progression-free survival was 22 vs. 6 months ( p = 0. 06), overall survival was 37 vs. 8 months ( p = 0. 11), complete response rates were 51% vs.
30% ( p = 0. 05), and refractory disease rates were 14% vs. 32% ( p = 0. 04). The single nucleotide polymorphism in CD19 was shown to influence the treatment outcome in FMC63-anti-CD19-CAR-T cell therapy, and the CD19 minor allele L174 predicted a favorable treatment outcome.
论文信息
- 作者
- Seipel K、Abbühl M、Bacher U、Nilius H、Daskalakis M、Pabst T
- 第一作者单位
- Department for Biomedical Research, University of Bern, 3008 Bern, Switzerland.Switzerland
- 通讯作者单位
- Department of Medical Oncology, Inselspital, Bern University Hospital, 3010 Bern, Switzerland.Switzerland
- 期刊
- Cancers2023 Jun 5
- 原文标识
- PubMed 37297020 · DOI 10.3390/cancers15113058
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →